Cellix Bio Pharma completes the acquisition of Avaca Pharma, a formulation development company. Avaca Pharma services include discovery, formulation development, regulatory support, and product development activities.
The acquisition of Avaca Pharma provides Cellix Bio Pharma with world-class expertise in NME/NCE discovery R&D services and a unique and extensive set of high-content and complex formulations. Combined with Cellix Bio’s established small molecule discovery and drug development capabilities, this expansion uniquely position Cellix Bio Pharma as a leading provider of integrated R&D services across both large and small molecule platforms and provides a base for further expansion.
With a vision of an innovative approach of execution, exceptional customer service, and focus on providing value, Cellix Bio Pharma is delighted to offer expanded leading-edge service solutions.
Avaca Pharma Research and Development Centre (RDC) at IDA Pashamylaram, Hyderabad, has a total high-quality compliant space of 6000 Sq. ft. in a 1.2-acre location, of which Formulation R&D occupies 3000 sq. ft. and Analytical Operations 3000 sq. ft. with provisions for expansion.
Avaca Pharma Commercial Operations Centre (COC) is located between Hyderabad and Vijayawada, Andhra Pradesh, and the new planned construction will host commercial manufacturing, packaging, analytical, and warehousing facilities within the 14 acres environmentally friendly campus. The facility will have a total built up cGMP space of 126,685 sq.ft. meeting regulatory compliance standards.